DELFI Diagnostics Presents Additional Promising Proof-of-Concept Data on its Monitoring Program at AACR 2023

/PRNewswire/ -- DELFI Diagnostics, Inc., a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection...

Related Keywords

United States ,Utrecht ,Netherlands ,American ,Nicholos Dracopoli ,Peter Bach ,Diagnostics Inc ,American Association For Cancer Research ,Netherlands Cancer Institute ,University Medical Center Utrecht ,Translational Research ,American Association ,Cancer Research ,Tumor Fraction ,Tumor Agnostic ,Chief Scientific ,Delfi Diagnostics ,